May 28, 2015

Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial

Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Analysis will be presented on June… Read More
learn more
May 28, 2015

Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community

Technology experts and cancer patient advocates will #HackGBM in Chicago this week Technology experts and cancer patient advocates will #HackGBM in Chicago this week May 28, 2015 03:59 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Novocure, a… Read More
learn more
May 28, 2015

Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community

Technology experts and cancer patient advocates will #HackGBM in Chicago this week Technology experts and cancer patient advocates will #HackGBM in Chicago this week May 28, 2015 03:59 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Novocure, a… Read More
learn more
May 28, 2015

Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial

Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Analysis will be presented on June… Read More
learn more
May 28, 2015

Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial

Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients Analysis will be presented on June… Read More
learn more
May 28, 2015

Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community

Technology experts and cancer patient advocates will #HackGBM in Chicago this week Technology experts and cancer patient advocates will #HackGBM in Chicago this week May 28, 2015 03:59 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Novocure, a… Read More
learn more
May 27, 2015

Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer… Read More
learn more
May 27, 2015

Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer… Read More
learn more
May 27, 2015

Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer… Read More
learn more
May 13, 2015

Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015

Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14… Read More
learn more